The aim of the Acarbose Cardiovascular Evaluation (ACE) clinical trial is to establish if a drug called acarbose can prevent people with coronary heart disease and impaired glucose tolerance (IGT) from experiencing, or dying from, further heart attacks and strokes. The ACE Trial is also looking to see if acarbose, which reduces blood glucose following a meal, can prevent or delay people progressing from IGT to type 2 diabetes. This is a phase IV multinational trial which began in 2008. It is being conducted in around 150 hospitals in mainland China and Hong Kong.
ACE Randomisation Target Achieved
14 September 2015
Professor Rury Holman has congratulated the ACE team on reaching the 6,500 randomised target.